NewsIRRAS appoints Dr. Christos Panotopoulos to new role as Special Advisor and a member of the IRRAS Clinical Advisory Board

IRRAS appoints Dr. Christos Panotopoulos to new role as Special Advisor and a member of the IRRAS Clinical Advisory Board

Stockholm, Sweden, May 9, 2018 – IRRAS AB (NASDAQ Stockholm: IRRAS), a commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for various brain pathologies, today announced that its scientific founder Dr. Christos Panotopoulos, M.D., Ph.D., has been appointed to a new role as Special Advisor and a member of the IRRAS Clinical Advisory Board. Concurrently with his new position, Dr. Panotopoulos will transition from his prior role as Chief Scientific Officer and member of the management team effective June 1, 2018.

“Dr. Christos Panotopoulos is the scientific founder of IRRAS and one of our industry’s leading neurosurgeons. He was instrumental in the development of the company’s products. We are thrilled to appoint Dr Panotopoulos asSpecial Advisor and a member of the IRRAS Clinical Advisory Board,” said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS. “As our company advances, his clinical work will be strategic to advise IRRAS on the growth of our IRRAflow™ product pipeline. Dr. Panotopoulos will also focus on expanding our network of clinical advisors and further establishing the clinical utility of our products in neurosurgery and other surgical pathologies.”

“I am happy to assist IRRAS in its mission to transform the treatment of intracranial bleedings and look forward to expanding our clinical advisory network as we introduce our products into new pathologies”, said Dr. Panotopoulos. “Since the commercial launch in the EU in May 2017, the ongoing post market survey has demonstrated absence of blockage and infection for more than a hundred consecutive patient treatments in Germany, in different intracranial pathologies.

It is well established that blockage and infection compromise significantly neurosurgical patients’ outcomes and increase significantly patient days in the hospital and costs to hospitals and healthcare providers” continued Dr. Panotopoulos.

For more information, please contact:

Fredrik Alpsten
CFO and Deputy CEO
+46 706 67 31 06
fredrik.alpsten@irras.com